A Phase I/II study of XX administered in combination with immunotherapy to patients with advanced solid tumors
- Medical indication: Metastatic non-squamous Non-Small-Cell Carcinoma (NSCLC) & Renal Cell Carcinoma (RCC) resistant to immunotherapy
- Subjects: 42 patients with Stage IV non-squamous NSCLC /RCC who have not achieved a measurable CR or PR to 1st line induction with a standard-of-care, PDL1-based immunotherapy regimen
- Study drugs: XX; Pembrolizumab & Pemetrexed (NSCLC); Pembrolizumab & Axitinib (RCC)
- Countries / Sites: France, Belgium, Canada / 20 sites
- Biotrial services: Project management • Regulatory submissions • Sites identification, selection & qualifications • Sites contracting & payment support • Clinical monitoring & site management • Medical monitoring • Pharmacovigilance • DSUR authoring & distribution • Data management • Statistical analysis • Medical writing • Central imaging
Hemato A Phase 1 dose escalation and expansion study in patients with previously treated relapsed or refractory multiple myeloma
A Phase 1 dose escalation and expansion study of XX in patients with previously treated relapsed or refractory multiple myeloma
- Medical indication: Relapsed or refractory multiple myeloma
- Subjects: 58 patients
- Study drugs: XX, monoclonal antibody
- Countries / Sites: UK, France / 6 sites
- Biotrial services: Project management • Regulatory submissions • Sites identification, selection & qualifications • Sites contracting & payment support • Clinical monitoring & site management • Data management • Statistical analysis • Medical writing